Who
James Caruso V
President & CEO
Company insider
Files Form 4 as: President & CEO, Cellectar Biosciences; Chief Commercial Officer, Allos Therapeutics.
In numbers
- Trades disclosed
- 76
- Buys
- 12
- Sells
- 14
- Bought
- $301K
- Sold
- $3.0M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 5 Jun 2006
- Last trade
- 7 Jul 2026
- Last filed
- 8 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Jul 2026filed 8 Jul 2026 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 7 Jul 2026filed 8 Jul 2026 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 7 May 2026filed 11 May 2026 | CLRB Cellectar BiosciencesBiotechnology | SEC FORM 4 Bought | $25K8,680 at $2.88 | filing |
| 7 May 2026filed 11 May 2026 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code P | $26026,040 at $0.01 | filing |
| 7 May 2026filed 11 May 2026 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code P | $26026,040 at $0.01 | filing |
| 7 May 2026filed 11 May 2026 | CLRB Cellectar BiosciencesBiotechnology | SEC FORM 4 Bought | $25K8,680 at $2.88 | filing |
| 2 Jul 2025filed 3 Jul 2025 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code P | $10010,000 at $0.01 | filing |
| 2 Jul 2025filed 3 Jul 2025 | CLRB Cellectar BiosciencesBiotechnology | SEC FORM 4 Bought | $50K10,000 at $4.99 | filing |
| 14 Feb 2025filed 18 Feb 2025 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —900,000 at $0.00 | filing |
| 14 Jun 2024filed 18 Jun 2024 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —900,000 at $0.00 | filing |
| 8 Dec 2023filed 12 Dec 2023 | CLRB Cellectar BiosciencesBiotechnology | SEC FORM 4 Code A | —40,596 at $0.00 | filing |
| 23 Jun 2023filed 12 Dec 2023 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —261,000 at $0.00 | filing |
| 17 Jan 2023filed 18 Jan 2023 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —261,000 at $0.00 | filing |
| 25 Jan 2022filed 27 Jan 2022 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,419,000 at $0.00 | filing |
| 4 Mar 2021filed 5 Mar 2021 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,600,000 at $0.00 | filing |
| 4 Mar 2021filed 5 Mar 2021 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code S | $8,92046,948 at $0.19 | filing |
| 4 Mar 2021filed 5 Mar 2021 | CLRB Cellectar BiosciencesBiotechnology | SEC FORM 4 Bought | $8,6705,100 at $1.70 | filing |
| 28 Dec 2020filed 28 Dec 2020 | CLRB Cellectar BiosciencesBiotechnology | SEC FORM 4 Bought | $50K37,037 at $1.35 | filing |
| 5 Jun 2020filed 8 Jun 2020 | CLRB Cellectar Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code P | $10910,870 at $0.01 | filing |
| 5 Jun 2020filed 8 Jun 2020 | CLRB Cellectar BiosciencesBiotechnology | SEC FORM 4 Bought | $25K21,740 at $1.15 | filing |
News
Cellectar Biosciences Eyes 2027 FDA Filing For Iopofosine In Waldenström PatientsCLRB · rttnews.com · 15 Oct 2026
0 headlines in the last 90 days name James Caruso V; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.